AAV VECTORS TARGETING T-CELLS

The disclosure provides variant AAV capsid proteins and AAV capsids and virus vectors comprising the same. The virus vectors described herein may have increased transduction in a target cell of interest, such as a T-cell, compared to native AAV capsid sequences. The disclosure also provides methods...

Full description

Saved in:
Bibliographic Details
Main Author SMITH, James Kennon
Format Patent
LanguageEnglish
French
Published 22.12.2022
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The disclosure provides variant AAV capsid proteins and AAV capsids and virus vectors comprising the same. The virus vectors described herein may have increased transduction in a target cell of interest, such as a T-cell, compared to native AAV capsid sequences. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a patient in need thereof. La divulgation concerne des variants de protéines de capside de VAA et des capsides de VAA ainsi que des vecteurs viraux les comprenant. Les vecteurs viraux de la présente divulgation peuvent avoir une transduction accrue dans une cellule cible d'intérêt, telle qu'un lymphocyte T, par comparaison avec des séquences de capside de VAA natives. La divulgation concerne également des méthodes d'administration des vecteurs viraux et des capsides de virus de la divulgation à une cellule ou à un patient en ayant besoin.
Bibliography:Application Number: WO2022US12542